Merck and Company

MRK
Delayed Nyse - 07/19 10:00:10 pm
81.39USD
-1.57%
Prev.82.6900
Open82.7000
High82.8200
Low81.1500
Volume11 501 694
Financials
Sales 2019 44 670 M
EBIT 2019 15 116 M
Net income 2019 10 053 M
Debt 2019 18 019 M
Yield 2019 2,73%
P/E ratio 2019 20,2x
P/E ratio 2020 16,5x
EV / Sales2019 5,09x
EV / Sales2020 4,76x
Capitalization 210 B
Company
Merck and Company specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (73.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory,...
Sector :
Pharmaceuticals - NEC
Calendar :
2019-07-23 Presentation
Trading Rating :
Investor Rating :
Latest news
07/18MERCK AND : FDA Approves Merck's RECARBRIO For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections
AQ
07/18Intermolecular Stockholders Agree to Merck KGaA Acquisition
DJ
07/17AYTU BIOSCIENCE'S "BIG 4" : Natesto®, Tuzistra® XR, ZolpiMist(TM), And MiOXSYS® Expected To Cause A Surge In Q4 Revenue (NASDAQ: AYTU)
AQ
07/17The end of inflated pharma pricing?
07/17MERCK AND : Bacterial-Infection Drug Recarbrio Approved by FDA
DJ
07/17MERCK AND : FDA Approves Merck's RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available
BU
07/16TRACKINSIGHT : No limit! S&P500, DJIA and Nasdaq Composite hitting new highs
TI
07/16MERCK AND : Thinking about trading options or stock in AMD, Alibaba, Merck, Roku, or Tesla?
PR
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBullishBullish
Resistance83,586,985,6
Spread/Res.-2,6%-6,3%-4,9%
Spread/Supp.2,8%2,8%6,7%
Support79,279,276,3